Prediction: Eli Lilly Will Be Worth $2 Trillion by 2031

Eli Lilly is positioned to become the first healthcare company to reach a $2 trillion market cap by 2031, requiring a 12.7% compound annual growth rate. The company's GLP-1 drug portfolio, led by tirzepatide (Mounjaro/Zepbound), is expected to drive strong revenue growth despite increasing competition. Additional growth catalysts include new product launches like Foundayo, pipeline candidates such as retatrutide, and AI-driven cost efficiencies across the organization.

08/01/2026, 4:17 PM • The Motley Fool

Eli Lilly Stock Has Skyrocketed. Novo Nordisk Has Crashed. 1 Number Explains Why They're Not Even Close Anymore.

Eli Lilly has significantly outperformed Novo Nordisk in the booming GLP-1 obesity drug market, with Lilly commanding 60% market share compared to Novo's smaller portion of the combined 87% duopoly. While the obesity drug market is projected to grow from $66 billion in 2025 to $120 billion by 2030, Lilly's stock has surged 58% over 52 weeks, whereas Novo has plummeted 62% since July 2024. However, Novo's recent launch of a pill-form obesity drug could shift the competitive landscape.

07/31/2026, 1:30 PM • The Motley Fool

Novo Nordisk provides update on the ZEUS phase 3 trial in people with ASCVD, CKD and inflammation

Novo Nordisk announced that ziltivekimab failed to meet its primary endpoint in the ZEUS phase 3 trial, showing no significant reduction in major adverse cardiovascular events (MACE) despite achieving the expected biological effect of IL-6 pathway inhibition. The drug demonstrated a hazard ratio of 0.99 versus placebo in patients with atherosclerotic cardiovascular disease, chronic kidney disease, and inflammation. The company will take a non-cash impairment charge in Q3 2026 but maintains its 2026 profit outlook and plans to continue two additional cardiovascular trials (HERMES and ARTEMIS) expected to report in H1 2027.

07/31/2026, 7:21 AM • GlobeNewswire

Watch Out, Eli Lilly and Novo Nordisk: Amgen's Monthly Weight Loss Drug Has 6 Phase 3 Trials Running -- and It's Coming for Your Patients

Amgen is developing MariTide, a monthly weight loss injection, to compete with Eli Lilly's and Novo Nordisk's weekly GLP-1 drugs. While the monthly dosing offers convenience, MariTide's phase 2 efficacy data don't suggest it will outperform competitors. Eli Lilly and Novo Nordisk are advancing newer therapies including oral and combination drugs, positioning them ahead of Amgen in the competitive weight loss market.

07/29/2026, 7:30 AM • The Motley Fool

Novo Nordisk A/S - share repurchase programme

Novo Nordisk continues its DKK 15 billion share repurchase programme, having repurchased 25.9 million B shares worth DKK 7.16 billion as of 24 July 2026. The company has also filed a false advertising lawsuit against Eli Lilly over misleading GLP-1 medicine advertising campaigns.

07/27/2026, 6:48 AM • GlobeNewswire

2 Top Growth Stocks to Buy Right Now Without Any Hesitation

The article recommends Eli Lilly and Intuitive Surgical as outstanding healthcare stocks to buy. Eli Lilly is positioned as a leader in the rapidly growing weight management medicine market with approved drugs like Zepbound and Foundayo, plus promising pipeline candidates like retatrutide. Intuitive Surgical, despite recent underperformance and headwinds, is viewed as a buying opportunity due to the successful launch of its da Vinci 5 surgical system and strong long-term prospects driven by innovation and high switching costs.

07/24/2026, 12:30 AM • The Motley Fool

Want Income for Life? Here Are 3 Stocks to Buy Now and Never Sell.

The article recommends three dividend stocks suitable for long-term buy-and-hold investors: Pfizer, which is developing new blockbuster drugs and entering the obesity drug market; Coca-Cola, with 64 years of consecutive dividend increases and a resilient business model; and Brookfield Renewable, which offers recurring income from renewable energy assets with 5-9% annual dividend growth targets.

07/22/2026, 11:23 AM • The Motley Fool

New study finds GLP-1 receptor agonists associated with lower risk of alcohol-related hospitalization among adults with alcohol use disorder

A multi-system study analyzing electronic health records from over 40,000 adults with alcohol use disorder found that GLP-1 receptor agonists (semaglutide and tirzepatide) were associated with 22-26% lower risk of alcohol-related hospitalization in patients with type 2 diabetes, and 32% lower risk in patients with obesity, compared to alternative treatments. Researchers emphasize the need for randomized clinical trials to establish causation.

07/21/2026, 6:45 PM • GlobeNewswire

"Deceptive Advertising!" Claims Novo Nordisk in Explosive New GLP-1 Lawsuit Against Eli Lilly. Here's What That Means for Both Stocks.

Novo Nordisk has filed a federal lawsuit against Eli Lilly, alleging deceptive advertising in GLP-1 weight-loss drug marketing. Novo claims Lilly's ads unfairly compare outdated lower doses of Wegovy to higher doses of Zepbound, ignoring the FDA-approved 7.2 mg Wegovy dose (approved March 2025) which shows comparable weight loss results. Lilly maintains its ads are accurate based on the 2024 SURMOUNT-5 head-to-head trial. The lawsuit seeks an injunction, corrective advertising, and damages, though analysts believe the impact on both stocks is likely minimal.

07/21/2026, 5:34 PM • The Motley Fool

Novo Nordisk's Dividend Story Is Changing -- Here's What Investors Are Missing

Novo Nordisk offers an attractive 3.5% dividend yield backed by a shifting business model focused on volume-driven growth in GLP-1 weight-loss drugs. Despite 2026 being a transition year with pricing pressures and generic competition, the company's strong pill formulation demand and solved supply issues position it well. The stock trades below five-year valuation averages, making it appealing for dividend investors seeking recurring income similar to its insulin business.

07/21/2026, 9:15 AM • The Motley Fool

Could Pfizer Ultimately Be the Biggest Winner in the $100 Billion Weight-Loss Market?

Pfizer is positioning itself as a contender in the rapidly growing $100 billion weight-loss drug market through its acquisition of Metsera and development of promising GLP-1 candidates like MET-097i, which showed strong efficacy with potential monthly dosing. However, the company faces stiff competition from Eli Lilly and Novo Nordisk, who currently lead the market with more advanced triple agonist drugs. While Pfizer may not dominate the space, it is well-positioned to be a significant player, and the company has other growth drivers including oncology pipeline and a high dividend yield of 6.9%.

07/20/2026, 3:15 AM • The Motley Fool

Fangzhou Launches Novo Nordisk’s Once-Weekly Basal Insulin/GLP-1 Therapy in China

Fangzhou Inc. (HKEX: 06086), a leading AI-driven Internet healthcare provider, announced the launch of Kyinsu®, the world's first once-weekly basal insulin/GLP-1 RA combination therapy, on its platform in collaboration with Novo Nordisk. The launch leverages Fangzhou's AI-enabled chronic disease management ecosystem to improve patient access to innovative diabetes treatments in China, the world's largest diabetes market with approximately 148 million adults living with diabetes.

07/19/2026, 10:15 PM • GlobeNewswire

The Most Overlooked Reason Eli Lilly Stock Keeps Surging -- and It Has Nothing to Do With Weight Loss

While Eli Lilly's GLP-1 weight-loss drugs (Mounjaro and Zepbound) account for nearly two-thirds of revenues with strong growth, the company is strategically using profits from these drugs to build a diversified pipeline in immunology, oncology, and neuroscience through acquisitions like AtaiBeckley and Ventyx Biosciences. Non-weight-loss drugs are already showing 160% revenue growth, positioning Eli Lilly for long-term success beyond the limited patent life of GLP-1 drugs.

07/17/2026, 9:15 PM • The Motley Fool

Wegovy Pill Just Changed the GLP-1 Market. Here's Why Eli Lilly Stock Could Still Win

Novo Nordisk's oral Wegovy launch has regained market share in the GLP-1 weight-loss drug market, capturing ~89% of oral weight-loss medication prescriptions in the U.S. However, Eli Lilly's Foundayo has potential advantages including fewer food restrictions and upcoming label expansions for multiple indications. Both companies remain well-positioned in the fast-growing anti-obesity market with strong pipelines.

07/17/2026, 2:30 PM • The Motley Fool

Clinical Stage Partnering Terms and Agreements in Pharmaceuticals and Biotechnology 2020-2026 | Benchmark More Than 1,800 Biopharma Deals with Various Indexes

ResearchAndMarkets.com released a comprehensive report analyzing over 1,859 clinical-stage pharmaceutical and biotechnology partnership deals announced since 2020. The report provides detailed financial terms, deal structures, contract documents, and insights into negotiation dynamics for clinical-stage drug development collaborations, serving as a benchmarking resource for biopharma dealmakers.

07/17/2026, 6:48 AM • GlobeNewswire